Pfizer’s Inlyta gets EU approval for advanced kidney cancer
Available as second-line therapy after treatment with pharma firm’s own Sutent
Read More
Section: Sales
Valeant offers $2.6bn to buy dermatology firm Medicis
Possible further addition to long list of Canadian pharma firm’s acquisitions
Read More
Senior appointments at NextPharma Technologies
Andrew Kelley, Pierre Delavaud and Matthew Wilder join the contract manufacturing organisation
Read MoreEMA grants accelerated assessment to Ariad’s leukaemia drug
Could cut months off approval decision for ponatinib
Read MoreAstellas wins US approval for prostate cancer drug Xtandi
Pharma company and its partner Medivation gain FDA licence for type of late-stage prostate cancer
Read More